Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00411892 · ClinicalTrials.gov registry record · Phase 3
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Terminated
- Registry status
- Phase 3
- Development phase
- 196
- Enrollment target
NCT00411892 is a Phase 3 study that was terminated before completion, run by Novo Nordisk A/S. The registered enrollment target is 196 participants.
The verdict
NCT00411892, a Phase 3 study, was terminated before completion, sponsored by Novo Nordisk A/S.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 196 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA). This trial will compare the changes in HbA1c after 26 weeks of inhaled insulin and pioglitazone combination therapy versus pioglitazone treatment alone.
Interventions
- DRUG pioglitazone
- DRUG inhaled human insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2006-11-29 |
| Est. Completion | 2008-03-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00411892
The ClinicalTrials.gov registry entry for NCT00411892 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 196 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pioglitazone is the first listed.
NCT00411892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00411892 about?
NCT00411892 is a clinical study titled "Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes". This trial is conducted in the United States of America (USA). This trial will compare the changes in HbA1c after 26 weeks of inhaled insulin and pioglitazone combination therapy versus pioglitazone treatment alone.
What is the current status of trial NCT00411892?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 196 participants. The study started on 2006-11-29. Estimated completion is 2008-03-18.
What interventions are being tested in trial NCT00411892?
The interventions under investigation include: pioglitazone (DRUG), inhaled human insulin (DRUG).
Who is sponsoring clinical trial NCT00411892?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.